Comparing Trimedyne (OTCMKTS:TMED) and Nexalin Technology (NASDAQ:NXL)

Nexalin Technology (NASDAQ:NXL) and Trimedyne (OTCMKTS:TMED) are both business services companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Nexalin Technology and Trimedyne”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$110,000.00	287.86	-$4.65 million	($0.72)	-4.15
Trimedyne	N/A	N/A	N/A	N/A	N/A

Trimedyne has lower revenue, but higher earnings than Nexalin Technology.

Insider and Institutional Ownership

0.7% of Nexalin Technology shares are held by institutional investors. 24.0% of Nexalin Technology shares are held by company insiders. Comparatively, 11.1% of Trimedyne shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Nexalin Technology and Trimedyne, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	0	0	1	0	3.00
Trimedyne	0	0	0	0	0.00

Nexalin Technology currently has a consensus target price of $3.00, indicating a potential upside of 0.33%. Given Nexalin Technology’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Nexalin Technology is more favorable than Trimedyne.

Profitability

This table compares Nexalin Technology and Trimedyne’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,578.81%	-213.51%	-173.41%
Trimedyne	N/A	N/A	N/A

Summary

Nexalin Technology beats Trimedyne on 6 of the 9 factors compared between the two stocks.

About Nexalin Technology

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

About Trimedyne

Trimedyne, Inc. manufactures and sells lasers, and disposable and reusable fiber-optic laser devices for use in the medical field. It offers lasers, fibers, needles, and switch tips for use in orthopedics, urology, ear and nose surgery, throat surgery, gynecology, gastrointestinal surgery, general surgery, and other medical specialties. The company also provides 80 watt and 30 watt holmium lasers, and side firing laser needles to treat herniated or ruptured spinal discs. In addition, it engages in the provision of services, and rental of lasers and other medical equipment to hospitals and surgery centers on a fee-per-case basis. The company operates in Asia, Europe, Latin America, the Middle East, Australia, and internationally. It markets its products through commission sales representatives in the United States and independent distributors internationally. Trimedyne, Inc. was founded in 1980 and is based in Irvine, California.